KR102312294B1 - 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도 - Google Patents

글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도 Download PDF

Info

Publication number
KR102312294B1
KR102312294B1 KR1020167013675A KR20167013675A KR102312294B1 KR 102312294 B1 KR102312294 B1 KR 102312294B1 KR 1020167013675 A KR1020167013675 A KR 1020167013675A KR 20167013675 A KR20167013675 A KR 20167013675A KR 102312294 B1 KR102312294 B1 KR 102312294B1
Authority
KR
South Korea
Prior art keywords
eosinophilic
compound
formula
general formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167013675A
Other languages
English (en)
Korean (ko)
Other versions
KR20160078400A (ko
Inventor
블라디미르 에브제니에비치 네볼씬
타치아나 알렉산드로브나 크로모바
아나스타샤 블라디미로브나 리들로프스카야
알렉산드르 그리고리예비치 츄찰린
Original Assignee
오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” filed Critical 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈”
Priority to KR1020207013125A priority Critical patent/KR102312013B1/ko
Publication of KR20160078400A publication Critical patent/KR20160078400A/ko
Application granted granted Critical
Publication of KR102312294B1 publication Critical patent/KR102312294B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167013675A 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도 Expired - Fee Related KR102312294B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207013125A KR102312013B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2013150861 2013-11-14
PCT/RU2014/000855 WO2015072893A1 (ru) 2013-11-14 2014-11-12 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013125A Division KR102312013B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도

Publications (2)

Publication Number Publication Date
KR20160078400A KR20160078400A (ko) 2016-07-04
KR102312294B1 true KR102312294B1 (ko) 2021-10-15

Family

ID=53057723

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167013675A Expired - Fee Related KR102312294B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도
KR1020207013125A Expired - Fee Related KR102312013B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207013125A Expired - Fee Related KR102312013B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도

Country Status (23)

Country Link
US (2) US9949962B2 (enExample)
EP (2) EP3466425B1 (enExample)
JP (4) JP2016540749A (enExample)
KR (2) KR102312294B1 (enExample)
CN (2) CN105722511B (enExample)
AU (2) AU2014349246C1 (enExample)
BR (1) BR112016010515B1 (enExample)
CA (1) CA2930231C (enExample)
CY (1) CY1122500T1 (enExample)
DK (1) DK3069720T3 (enExample)
EA (4) EA032955B3 (enExample)
ES (2) ES2836887T3 (enExample)
HU (1) HUE046671T2 (enExample)
IL (2) IL245429B (enExample)
LT (1) LT3069720T (enExample)
MX (2) MX365781B (enExample)
PL (2) PL3069720T3 (enExample)
PT (1) PT3069720T (enExample)
RU (1) RU2552929C1 (enExample)
SG (1) SG10201900504XA (enExample)
SI (1) SI3069720T1 (enExample)
UA (1) UA118687C2 (enExample)
WO (1) WO2015072893A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
EP2985282A4 (en) * 2013-04-12 2017-02-22 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
MD4788C1 (ro) * 2017-09-07 2022-09-30 Ооо "Валента-Интеллект" Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US20210315941A1 (en) * 2020-04-07 2021-10-14 Hofseth Biocare Asa Respiratory treatments using salmonid oil compositions
WO2021262040A1 (ru) * 2020-06-26 2021-12-30 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365210A1 (en) 1988-10-11 1990-04-25 Kyowa Hakko Kogyo Co., Ltd. Hydroxamic acid derivatives
WO1992011011A1 (en) 1990-12-24 1992-07-09 Merrell Dow Pharmaceuticals Inc. Use of certain glutarimide derivatives in the treatment of depression and mania
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
ES2320638T3 (es) 2001-11-07 2009-05-27 Cytos Biotechnology Ag Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico.
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
EP2985282A4 (en) 2013-04-12 2017-02-22 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365210A1 (en) 1988-10-11 1990-04-25 Kyowa Hakko Kogyo Co., Ltd. Hydroxamic acid derivatives
WO1992011011A1 (en) 1990-12-24 1992-07-09 Merrell Dow Pharmaceuticals Inc. Use of certain glutarimide derivatives in the treatment of depression and mania
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors

Also Published As

Publication number Publication date
SG10201900504XA (en) 2019-02-27
DK3069720T3 (da) 2019-11-25
IL271352B (en) 2021-04-29
EP3069720A4 (en) 2017-06-21
JP6758677B2 (ja) 2020-09-23
EA032955B1 (ru) 2019-08-30
EA201891262A1 (ru) 2018-10-31
LT3069720T (lt) 2020-01-10
PL3466425T3 (pl) 2021-04-06
JP2020002152A (ja) 2020-01-09
ES2836887T3 (es) 2021-06-28
PT3069720T (pt) 2019-12-02
EA032955B3 (ru) 2020-02-27
PL3069720T3 (pl) 2020-05-18
JP6589251B2 (ja) 2019-10-16
JP2019055953A (ja) 2019-04-11
SI3069720T1 (sl) 2020-02-28
EP3069720A1 (en) 2016-09-21
AU2014349246B2 (en) 2018-10-18
BR112016010515A2 (enExample) 2017-08-08
EA201990529A1 (ru) 2019-07-31
CA2930231A1 (en) 2015-05-21
CN105722511B (zh) 2019-09-17
RU2552929C1 (ru) 2015-06-10
EP3069720B1 (en) 2019-10-30
CN105722511A (zh) 2016-06-29
IL245429B (en) 2020-02-27
EP3466425B1 (en) 2020-10-07
EA201690798A1 (ru) 2016-08-31
EA037447B1 (ru) 2021-03-30
BR112016010515B1 (pt) 2022-09-27
MX2019006881A (es) 2019-08-01
CN110200968A (zh) 2019-09-06
IL245429A0 (en) 2016-06-30
MX2016006330A (es) 2016-09-06
US20160279114A1 (en) 2016-09-29
KR20200053639A (ko) 2020-05-18
UA118687C2 (uk) 2019-02-25
CA2930231C (en) 2022-06-14
AU2014349246A1 (en) 2016-05-19
MX386887B (es) 2025-03-19
JP2016540749A (ja) 2016-12-28
EA030961B1 (ru) 2018-10-31
KR102312013B1 (ko) 2021-10-15
US10220029B2 (en) 2019-03-05
JP2019214606A (ja) 2019-12-19
US9949962B2 (en) 2018-04-24
EA032940B1 (ru) 2019-08-30
HUE046671T2 (hu) 2020-03-30
AU2014349246A9 (en) 2018-09-20
IL271352A (en) 2020-01-30
RU2013150861A (ru) 2015-05-20
CY1122500T1 (el) 2021-01-27
KR20160078400A (ko) 2016-07-04
ES2759530T3 (es) 2020-05-11
AU2014349246C1 (en) 2019-02-21
EA201891261A1 (ru) 2018-10-31
EP3069720A8 (en) 2017-10-04
WO2015072893A1 (ru) 2015-05-21
AU2018264084C1 (en) 2020-08-27
AU2018264084B2 (en) 2020-05-14
AU2018264084A1 (en) 2018-12-06
MX365781B (es) 2019-06-13
EP3466425A1 (en) 2019-04-10
US20180104230A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
KR102312294B1 (ko) 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도
BR112020019814A2 (pt) Tratamento de hidradenite supurativa usando inibidores jak
TWI729059B (zh) 2-羥吲哚化合物
BRPI0609650A2 (pt) inibidores heterobicìlicos de hvc
WO2022268083A1 (zh) 吡咯并嘧啶化合物及其药物组合物治疗慢性移植物抗宿主病的用途
HK40007097A (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK40007097B (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK1224930A1 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
HK1224930B (zh) 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途
EP4506007A1 (en) Composition for preventing or treating pulmonary fibrosis, comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
WO2025256633A1 (en) Method of treating moderate to severe active rheumatoid arthritis
WO2025002076A1 (zh) 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241007

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241007

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241007